title: Summaries for patients. Screening, monitoring, and treatment of early stage chronic kidney disease: recommendations from the American College of Physicians.
mesh_terms: D000328:Adult; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D058070:Asymptomatic Diseases / Q000628:therapy; D018450:Disease Progression; D004359:Drug Therapy, Combination; D015248:Gemfibrozil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007668:Kidney / Q000503:physiopathology; D008403:Mass Screening; D008991:Monitoring, Physiologic; D011507:Proteinuria / Q000175:diagnosis; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D015248:Gemfibrozil